Menu Search
Equities

Alexandria Real Estate Equities Inc

A6W:MUN

Alexandria Real Estate Equities Inc

Actions
  • Price (EUR)101.20
  • Today's Change2.80 / 2.85%
  • Shares traded20.00
  • 1 Year change+7.89%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.

  • Revenue in USD (TTM)3.18bn
  • Net income in USD282.55m
  • Incorporated1994
  • Employees568.00
  • Location
    Alexandria Real Estate Equities Inc26 North Euclid AvenuePASADENA 91101United StatesUSA
  • Phone+1 (626) 578-0777
  • Fax+1 (626) 578-0896
  • Websitehttps://www.are.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.